After the news broke that Vigil Neuroscience, Inc. (NASDAQ: VIGL) will be acquired by Sanofi (NASDAQ: SNY), the stock value of the firm surged. At $7.91 as of the most recent trading session, VIGL shares had surged 242.64%. Following a definitive merger agreement between the two companies, there was a sharp stock-price rise.
Terms of Acquisition and Benefits to Shareholders
Sanofi would pay $8.00 per share in cash for all of Vigil Neuroscience’s outstanding common shares, which, when fully diluted, would equal around $470 million in equity value.
Vigil shareholders will receive a $2.00 non-transferable Contingent Value Right (CVR) per share in addition to the upfront payment. This extra payment is subject upon the first commercial sale of VIGL’s main experimental treatment, VG-3927, within a predetermined window of time. The entire transaction value might be around $600 million if it is fulfilled.
VG-3927 and Alzheimer’s Research Advancements
The purchase is anticipated to hasten the development of VG-3927, a TREM2 agonist being developed for Alzheimer’s disease, and is consistent with Sanofi’s strategy focus on neurology. In order to restore neuroprotective capabilities that have been compromised in Alzheimer’s disease and other neurodegenerative diseases, VG-3927 addresses microglial activation.
In order to slow the course of dementia, TREM2 activation may improve microglial phagocytosis, migration, and survival. The clinical development and possible commercialization of VG-3927 are expected to be supported by Sanofi’s strong R&D infrastructure and worldwide footprint.
Closing Timeline and Shared Mission
Vigil expects the transaction to close in the third quarter of 2025, subject to customary closing conditions. Both companies emphasized their shared mission of delivering innovative therapies to address unmet medical needs, particularly in neurodegenerative diseases.
Exclusion of VGL101 from the Deal
Notably, Vigil’s monoclonal antibody program Iluzanebart (VGL101) is excluded from the acquisition. Prior to the completion of the deal, the exclusive licensing agreement with Amgen—original licensor of VGL101—will be terminated, and the program will be returned to Amgen.
Leave a Reply